Abstract
Background. Transplant renal artery stenosis (TRAS) is a recognized complication resulting in post-transplant hypertension associated with allograft dysfunction. It is a commonly missed but potentially treatable complication that may present from months to years after transplant surgery. In this retrospective study, we compared management strategies and outcomes of TRAS from 1990 to 2005. Methods. Case notes of transplant recipients with TRAS demonstrated by angiography were reviewed. Angiography and was carried out when there was a clinical or Doppler ultrasound suspicion of TRAS. The clinical diagnosis of TRAS was based on uncontrolled refractory/new-onset hypertension and/or unexplained graft dysfunction in the absence of another diagnosis, such as rejection, obstruction or infection. The two-tailed Student t-test was used to analyse the differences between mean arterial pressure, serum creatinine, and estimated glomerular filtration rate before and after the intervention. Results. Sixty-seven patients with angiogram-confirmed TRAS were included. Forty-four, 9 and 14 patients were managed with primary percutaneous transluminal renal angioplasty (PTRA), surgical intervention and conservative treatment, respectively. Uncontrolled hypertension was the most common presentation noted in 74.62%.
Introduction
Renal transplant is the treatment of choice for many patients with end-stage renal failure (ESRF) [1] . It is highly cost-effective [1, 2] compared with dialysis [3, 4] , and is also associated with higher long-term patient survival rates [5, 6] and improved quality of life [7] . However, there is a huge imbalance between organ availability and demand [2, 8] , which mandates that every renal transplant be optimized to achieve long-term patient and allograft survival.
Until recently, the main cause of premature graft loss was the result of host immune response [9] . In the last two decades, with the advent of calcineurin inhibitors (CNIs) and other newer immunosuppressive agents, there has been a significant progress in immunosuppressive potency to reduce acute and chronic rejection, which has reduced the 5-year graft loss to <20-30% [10, 11] . Thus, the other causes of premature graft loss are becoming more evident including recurrence of primary disease in allografts [12, 13] , infections [14, 15] , and urological [16, 17] and vascular complications [18, 19] . Of these complications, transplant renal artery stenosis (TRAS) is an underdiagnosed but potentially treatable complication that can occur from months to years after transplantation. Estimates of prevalence range widely from 1% to 23% in different series depending upon the criteria used to establish and manage the diagnosis [20, 21] . It frequently presents with worsening or refractory hypertension and/or allograft dysfunction in the absence of rejection, immunosuppressive toxicity, ureteric obstruction, or infection. It can also have an atypical presentation [22] [23] [24] . In this retrospective study, we analysed diagnosis, management and outcome of TRAS in recipients from 1990 to 2005.
Materials and methods

Clinical diagnosis, patient selection and baseline evaluation
The clinical diagnosis of TRAS was based on uncontrolled refractory or new-onset hypertension, and/or unexplained reduction in estimated glomerular filtration rate (eGFR). To obtain a homogenous and true patient population of TRAS, we excluded patients with primary or associated acute or chronic allograft rejection, recurrence of primary disease in allograft, urological complication, and/or infections. We recorded the patient's primary disease, time since transplant, donor type, number of arteries, and baseline mean serum creatinine (MSCr), diastolic blood pressure (BP) and systolic BP. Baseline MSCr level was calculated from the last three serum creatinine levels recorded before the clinical and/or radiological diagnosis was established in order to correct for any transient fluctuations in serum creatinine.
Evaluation and management
Clinical diagnosis of TRAS was further evaluated with Doppler ultrasound (dUS) and an angiography with or without angioplasty in the Department of Radiology.
Indications for Doppler ultrasound. All patients with uncontrolled refractory or new-onset hypertension, and/or unexplained allograft dysfunctions had dUS. During dUS, general graft characteristics including corticomedullary thickness, dilatation of pelvi-ureteric system, scarring, and arterial and venous vascular flows were all recorded. Peak systolic velocity (PSV) of >200 cm/s in the transplant renal artery was considered significant to support the diagnosis of TRAS.
Indications for angiography and angioplasty. All those patients with PSV of >200 cm/s in transplant renal artery with associated allograft dysfunctions or uncontrolled hypertension (new or refractory) had inpatient angiography with or without percutaneous transluminal renal angioplasty (PTRA). During angiography, site, size, length and number of stenosis were recorded (Figure 1 ). Primary PTRA was performed for stenoses of >60% diameter reduction (Figure 2 ). Stents were used in cases of inadequate response to balloon angioplasty due to elastic recoil ( Figure 3 ). Secondary PTRA was performed after failure of pharmacological treatment or failed surgery.
Indications for conservative (pharmacological) treatment. Patients with recent transplants who had moderate graft dysfunction and who showed Indications for surgery. Patients primarily considered unsuitable for radiological angioplasty because of recent transplant, multiple stenoses, long and narrow stenosis, or after failure of angioplasty were considered for surgery.
Outcome measurement and statistical analysis
Outcome was recorded in terms of improvement in serum creatinine levels, systolic and diastolic BP, and eGFR. Improvement was considered significant if there was <50% of residual stenosis, and >25% improvement in serum creatinine and eGFR levels after 12 weeks post-treatment. Graft failure was defined when patients were established on continuous maintenance dialysis. Data were reviewed for a minimum of 5 years during the follow-up period. Graft survivals at 1 and 5 years were calculated for all adult renal transplants performed, patients with TRAS included in the study and all the subgroups individually. Data (age, time to presentation, blood pressure and serum creatinine) were expressed as mean ± SD, or median and range as specified. Differences between BP, serum creatinine, and eGFR before and after treatment were analysed by a two-tailed Student t-test. Statistical Package for the Social Sciences (SPSS) was used for analysis. The statistical significance level was defined as P < 0.05.
Results
General demographics
One thousand seven hundred and twenty-seven adult renal transplants were performed between January 1990 and December 2005. During this period, 196 renal transplant angiograms were performed to confirm the diagnosis of TRAS; of which, 183 angiograms (10.59% of total transplants) confirmed the diagnosis. Out of those patients, 67 patients whose angiograms showed significant stenosis and who fulfilled our inclusion and exclusion criteria were included in this study (Table 1) . Fifty-nine of those patients had a significant graft dysfunction including 34 with associated sustained high BP. Eight patients had sustained high BP alone without a significant graft dysfunction.
Primarily, 44, 9 and 14 patients were managed by primary PTRA (pPTRA), surgery and conservative treatment, respectively ( Figure 4 ). The majority of cases were cadaver transplant recipients rather than living-donor recipients (59 vs 8). Mean time from transplant to presentation was 1.68 years. TRAS was most commonly found when there was a single artery with an end-to-side anastomosis (Table 2) .
Angioplasty
Among 67 patients included in the study, a total of 53 PTRA procedures were performed including 44 pPTRA and 9 secondary PTRA (sPTRA).
In the pPTRA group, 36 patients (81.81%, P < 0.05) showed improvement in graft function, whereas 8 patients showed no improvement in allograft functions (18.18%). Five patients were considered for surgery following an unsuccessful angioplasty. Secondary PTRA was performed in nine patients including seven after failed medical treatment and two after failed surgery. Four patients (44.44% of sPTRA), including both after failed surgery, showed no improvement in graft function. Stents were placed in 13 patients, 9 during pPTRA and 4 during sPTRA.
Surgery
A total of 16 surgical procedures were performed including 9 primary and 7 secondary procedures. In the primary surgery subgroup, four patients had improved graft function (44.44%), whereas five patients showed no improvement (55.55%). Two patients were considered for sPTRA. In the secondary surgery subgroup, four procedures were performed for acute presentation of pain and tenderness over the grafted kidney. During surgical exploration, uncontrolled bleeding was encountered in two patients, and allograft nephrectomy was performed. In two further patients, perfusion of the kidney post-anastomosis was not satisfactory, and nephrectomy was performed. Only one patient from this subgroup showed long-term improvement in allograft function. In this subgroup, five out of seven patients lost their graft. 
Pharmacological
After angiography, 14 patients were managed conservatively. This included eight patients within the first 3 months of their transplant, four had smaller calibre multiple artery renal transplants and two patients were planned for angioplasty at second stage; however, their graft functions started improving, and therefore, it was not attempted. In this subgroup, five patients (35.71%) showed improvement in graft functions; however, in nine (64.28%) patients, no improvement was recorded. It reflected a significant failure rate in this subgroup (P < 0.05).
Blood pressure. There was an initial improvement of BP observed in all groups; however, it was only significantly sustained in pPTRA (P < 0.05) ( Tables 3 and 4 ; Figures 5  and 6 ). Twenty-three patients needed mono-antihypertensive therapy, while 11 needed more than one antihypertensive to sustain blood pressure control.
Serum creatinine levels. Serum creatinine levels were recorded in micromoles per litre. A significant sustained improvement was seen in pPTRA (P < 0.05); however, there was no improvement seen in sPTRA (Table 5; Figure 7 ).
Estimated glomerular filtration rate. eGFR (mL/min) was calculated by MDRD equation [25] . Patients with pPTRA showed significantly sustained improvement in eGFR. Patients in the sPTRA group showed the worst prognosis (Table 6 ; Figure 8 ).
Graft survival. The graft survival for all the adult renal transplants performed during the study period (n = 1727) was 87.7% and 73%, respectively ( Figure 9 ). Overall, graft survival after treatment of TRAS at 1 and 5 years was 93% and 81%, respectively. Angioplasty had a higher incidence of graft survival at 91% at the first year and 86% at the fifth year. In comparison, surgery and medical treatment had 1-and 5-year graft survivals of 75% and 65%, and 85% and 63%, respectively ( Figure 10 ).
Discussion
The reported incidence of TRAS varies widely [20, 21] which may, in part, be due to underdiagnosis: deterioration in allograft function is more commonly attributed to rejection and infection [26] [27] [28] .
Post-transplant vascular complications are uncommon but important as they can result in significant graft dysfunction and may even result in loss of allograft. There are many causes of TRAS including small calibre and atherosclerosis of the donor artery, trauma to donor artery at procurement, presence or absence of arterial patch with its size and quality, trauma to recipient artery during surgery, suturing technique, and damage to the iliac artery during transplantation. TRAS is more common at the site of the anastomosis as compared with distal donor artery [29] . Transplant renal artery stenosis is more common in cadaveric kidney transplant recipients with new-onset or worsened hypertension [30] .
The treatment of TRAS includes PTRA or surgical intervention; however, a very small percentage of patients can be managed conservatively if the stenosis is mild and if the patient is asymptomatic with no deterioration of allograft function.
In this study, we have presented our experience with management of TRAS. The most common clinical pres-
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Angioplasty (53) Surgical (16) Medical (14) pPTRA (44) Primary (9) Secondary (7) Imp (5) no-Imp (9) sPTRA (9) 2 Imp*(36) No-Imp (8) No Imp (2) Imp (4) No Imp (3) Imp (2) No Imp (5) 7 Sug (5) No Imp (3) Imp (5) No Imp (4) *Improvement = 55 No improvement = 12 Transplant renal artery stenosisentation was uncontrolled hypertension, noticed in 45 patients (67%). In general clinical practice, this presentation is commonly missed. In a recent study, Krishnamoorthy et al. [31] showed 37% presenting with hypertension. In another study by Woo et al. [32] , they showed a very low predictive value of hypertension in diagnosis of TRAS as compared with allograft dysfunction and biopsy. We recommend a higher suspicion of TRAS in patients with hypertension. Angioplasty is by far the commonest initial mode of treatment. It has the benefit of being a minimally invasive procedure which can be performed as day case. In our study, pPTRA resulted in improvement in 82% of allografts. Angioplasty, in total, has also shown a graft survival of 93% at 1 year and 81% graft survival at 5 years. Very similar data were produced by Greenstein et al. [33] which showed 83% functional grafts after a mean interval of 30 months. However, Benoit et al. [34] showed better results with surgery as compared with percutaneous angioplasty (immediate success 92% vs 69%, and longterm success 81.5% vs 40.8%). He also observed a higher morbidity with angioplasty when compared with surgery (28% vs 7.8%). After our study, we recommend primary angioplasty as the primary mode of treatment with few exceptions. We emphasize that its success is operatordependent; therefore, early referral should be made to an interventional radiologist with experience and interest in transplant radiology.
Conservative management is associated with a higher risk of graft failure (65%). Therefore, we recommend an early intervention with angioplasty to preserve a good graft function and control of BP. The importance of early diagnosis is self-evident because delayed diagnosis is associated with a higher incidence of graft loss and other potentially fatal systemic complications, whereas cases promptly recognized and treated before irreversible structural changes of the graft develop may achieve full recovery and near normal function. 
Conclusions
TRAS is a complication of renal transplant which is associated with decreased graft survival and uncontrolled hypertension. Because clinical diagnosis is difficult, a high index of suspicion in the differential diagnosis of uncommon causes of allograft failure is mandatory. As early intervention results in an improved long-term patient and graft survival, we recommend an early Doppler ultrasound by an experienced sonographer to rule out this important diagnosis.
